Retatrutide vs Tirzepatide
Retatrutide vs Tirzepatide: head to head on weight-loss potential, mechanism, side effect profile, and current availability.
The verdict
Retatrutide adds a third receptor (glucagon) on top of the GLP-1 and GIP that Tirzepatide already covers, and its trial numbers are the largest weight-loss figures anyone has published for this class. The catch is maturity: Tirzepatide is FDA-approved and widely used, while Retatrutide is still working through trials. If you want a proven, available compound, Tirzepatide wins today. Retatrutide is the one to watch if the early effect size holds up through approval.
Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.
Tirzepatide is the prescription weight-loss drug sold as Mounjaro (diabetes) or Zepbound (weight loss). It hits two appetite-control receptors at once. Most users lose 15-20% of body weight over several months. One injection per week.
Which one should you pick?
Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.
Pick Tirzepatide if users who couldn't tolerate semaglutide or metabolic-syndrome adults under provider guidance.
Still torn between Retatrutide and Tirzepatide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.
Want the latest evidence updates?
Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.